Evaluation Of Efficacy Of Arbekacin In Drug-Resistant Bacterial Infections : A Study In a Tertiary Health Care Center Of South-East Region Of India
Keywords:
Arbekacin (ABK), Aminoglycoside, MRSA.Abstract
Arbekacin (ABK) is a novel aminoglycoside, which has been used to treat severe infections, especially MRSA and multi-drug resistant gram-negative infections including strains resistant to gentamicin (GM), tobramycin (TOB), and amikacin (AMK). Many studies including the study by Hwang et al, found that Arbekacin was non-inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment. This study was conducted to test the MDR Gram-negative isolates and the MRSA against Arbekacin by the E-test method.
MATERIALS & METHODS:
This prospective study was performed in the Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneshwar, Odisha, India, for a period of 12 months between Jan2023 to Feb 2024. The study included all the MDR Gram-negative isolates and the MRSA isolates which were isolated from the routine clinical samples in the department. Each isolate was inoculated onto a Mueller-Hinton agar plate and was tested for Arbekacin sensitivity by the Arbekacin E-test strip and MIC was noted.
RESULTS:
Total 168 number of drug resistant bacteria were tested in this study. Among them 128 (76.2%) were Gram negative bacteria and 40 (23.8%) were Gram positive bacteria. Among the Gram negative bacteria Klebsiella spp. 18 (20%), Escherichia coli 4 (18.2%), Acinetobacter spp 3 (50%), Proteus spp. 3 (75%), Pseudomonas spp 4 (100%), Enterobacter spp. 2 (100% ) were found to be sensitive to arbekacin. Among the Gram positive bacteria Staphylococcus aureus 22 ( 81.5%), Coagulase negative Staphylococcus 4 (100%), Enterococcus spp. 7 (77.8%) were found to be sensitive to arbekacin.
Conclusion
Since ABK shows good antibacterial activity against Gram-negative bacteria in addition to MRSA, it is recommended to use ABK for the treatment of multidrug-resistant bacterial infections. Therefore, it is expected that ABK will be a good potential antibiotic and also as an additional treatment option, such as in combination with other beta-lactams, for serious drug resistant bacterial infections.
